

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhaoke Ophthalmology Limited
兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

GRANT OF SHARE OPTIONS

Reference is made to the prospectus of the Company dated April 16, 2021, in relation to the principal terms of the Post-IPO Share Option Scheme adopted on April 1, 2021.

This announcement is made pursuant to Rule 17.06A of the Listing Rules. The Board is pleased to announce that on July 3, 2024, a total of 4,570,000 Share Options were granted by the Company to 23 Grantees, subject to acceptance by the Grantees and compliance with the Listing Rules and the terms of the Post-IPO Share Option Scheme.

Among the total of 4,570,000 Share Options, (i) 2,520,000 Share Options were granted to 16 Grantees who are employees of the Group and are not connected persons of the Company; and (ii) 2,050,000 Share Options were granted to seven Grantees who are either the Directors and/or chief executive of the Company.

The Share Options will entitle the Grantees to subscribe for up to a total of 4,570,000 new Shares which represent approximately 0.84% of the issued Shares as at the date of this announcement.

DETAILS OF THE SHARE OPTION GRANT

Set out below are the details of the Share Option Grant:

Grant Date: July 3, 2024

Exercise Price: HK\$1.40 per Share, which represents the highest of:

- (i) the closing price of HK\$1.40 per Share as stated in the Stock Exchange's daily quotation sheets on the Grant Date, which must be a Business Day;

(ii) the average closing price of HK\$1.40 per Share as stated in the Stock Exchange's daily quotation sheets for the five Business Days immediately preceding the Grant Date; and

(iii) the nominal value of US\$0.00000025 per Share.

Market price of the Shares on the Grant Date: HK\$1.40 per Share

Number of Grantees: 23

Consideration payable for the grant of Share Options for each Grantees upon acceptance: HK\$1.0

Number of Share Options granted: 4,570,000 Share Options

Vesting Period: The Share Options granted to all Grantees (including the Grantees who are Directors and/or chief executive of the Company) will vest in four equal installments, with the initial installment vesting on the Grant Date, followed by the remaining three installments vesting on each subsequent anniversary of the previous vesting date.

Performance targets:

The Share Options granted to the Grantees are not subject to any performance targets.

The remuneration committee of the Company is of the view that it is appropriate to grant the Share Options to the Grantees without any performance targets, and such arrangement is in line with the remuneration policy of the Company and the purpose of the Post-IPO Share Option Scheme, because: (i) the Share Option Grant is a recognition of the Grantees' contribution to the development of the Group and/or their continued efforts for bringing in objective insights and judgment to the Board, which would contribute to the sustainable development of the Company's business; (ii) the value of the Share Options will be linked to the future price of the Shares, which in turn depends on the performance of the Company. The Share Options vesting in four equal installments on a yearly basis will motivate the Grantees to remain with, and to strive for the future development of, the Group; and (iii) issuers generally should not grant equity-based remuneration with performance-related elements to independent non-executive directors pursuant to paragraph E.1.9 of Part 2 of Appendix C1 to the Listing Rules.

Option Validity Period:

Ten years, from July 3, 2024 to July 2, 2034 (both days inclusive)

Clawback mechanism:

All Share Options shall lapse automatically and not be exercisable under certain circumstances specified in the Post-IPO Share Option Scheme, including but not limited to the occurrence of (i) the Grantee ceasing to be an Eligible Participant under the Post-IPO Share Option Scheme by reasons of, among others, termination of employment or directorship, or being unable to pay or to have no reasonable prospect of being able to pay his debts, or having become insolvent, or having made any arrangements or composition with his creditors generally or being convicted of any criminal offence involving his integrity or honesty; (ii) the expiry of the Option Validity Period; and (iii) the commencement of the winding-up of the Company. Further details of the clawback mechanism are disclosed in the prospectus of the Company dated April 16, 2021.

The table below shows a breakdown of Share Options that were granted to (i) the Directors and/or chief executives of the Company; and (ii) the employees of the Group:

Name/Type of the Grantees	Position held with the Company/Group	Number of Share Options
Dr. Li Xiaoyi	Chairman of the Board, executive Director and the chief executive officer of the Company	800,000
Mr. Dai Xiangrong	Executive Director	500,000
Ms. Leelalertsuphakun Wanee	Non-executive Director	150,000
Ms. Tiantian Zhang	Non-executive Director	150,000
Mr. Wong Hin Wing	Independent non-executive Director	150,000
Prof. Lo Yuk Lam	Independent non-executive Director	150,000
Mr. Liew Fui Kiang	Independent non-executive Director	150,000
16 employees	Employees of the Group	<u>2,520,000</u>
Total		<u><u>4,570,000</u></u>

LISTING RULES IMPLICATIONS

Pursuant to Rule 17.04(1) of the Listing Rules and the terms of the Post-IPO Share Option Scheme, each grant of Share Options to a Director, chief executive or substantial shareholder of the Company or any of their respective associates, shall be subject to the approval by the independent non-executive Directors (and in the event that the Board offers to grant Share Options to an independent non-executive Director, the vote of such independent non-executive Director shall not be counted for the purposes of approving such grant). Accordingly, the Share Options granted to each of Dr. Li Xiaoyi, being the Chairman of the Board, an executive Director and the chief executive officer of the Company, Mr. Dai Xiangrong, being an executive Director, and Ms. Leelalertsuphakun Wane and Ms. Tiantian Zhang, being the non-executive Directors, has been approved by all the three independent non-executive Directors. The Share Options granted to each of the independent non-executive Directors as mentioned above has been approved by the other two independent non-executive Directors, such that no independent non-executive Director approved his own grant of Share Options.

The Grantee who is a Director has abstained from voting so far as the resolution for the approval of the grant of Share Options to him/her was concerned.

The purposes of the Post-IPO Share Option Scheme is to provide incentive or reward to Eligible Participants for their contribution to, and continuing efforts to promote the interests of, the Group, and to incentivize them to remain with the Group. The remuneration committee of the Company believes that the Share Option Grant is appropriate and in line with the market practice and the purposes of the Post-IPO Share Option Scheme.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, (a) save as disclosed herein, none of the Grantees is a Director, chief executive or substantial shareholder of the Company or their respective associates or otherwise a connected person of the Company; (b) none of the Grantees is a related entity participant or service provider (as defined in the Listing Rules); and (c) no financial assistance has been provided by the Group to the Grantees to facilitate the purchase of Shares under the Post-IPO Share Option Scheme. The grant of Share Options to each of the Grantees would not result in the Shares issued and to be issued in respect of all awards and options granted to a Grantee in the 12-month period up to and including the date of such grant representing in aggregate exceeding the 1% individual limit under Rule 17.03D of the Listing Rules. The grant of Share Options to each of the independent non-executive Directors would not result in the Shares issued and to be issued in respect of all options granted to any independent non-executive Director in the 12-month period up to and including the date of such grant representing in aggregate exceeding the 0.1% limit for the purpose of Rule 17.04(3) of the Listing Rules. None of the Share Option Grant will be subject to approval by the Shareholders.

The Share Option Grant will be satisfied by the issue of new Shares within the scheme mandate of the Post-IPO Share Option Scheme. After the above Share Option Grant, 41,125,550 Shares will be available for future grant under scheme mandate of the Post-IPO Share Option Scheme.

DEFINITIONS

In this announcement, the following expressions shall have the meaning set out below unless the context requires otherwise:

“associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Board”	the board of Directors of the Company
“Business Day(s)”	a day on which banks in Hong Kong are generally open for normal banking business to the public and which is not a Saturday, Sunday or public holiday in Hong Kong
“Company”	Zhaoke Ophthalmology Limited (兆科眼科有限公司)
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“Director(s)”	the director(s) of the Company
“Eligible Participant(s)”	the eligible participants as defined under the Post-IPO Share Option Scheme
“Grant Date”	July 3, 2024
“Grantee(s)”	the Share Option Grantee(s)
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Date”	April 29, 2022
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Post-IPO Share Option Scheme”	the post-IPO share option scheme adopted by the Company on April 1, 2021, effective from the Listing Date, as amended from time to time, the principal terms of which are set out in “Statutory and General Information – D. Share Option Schemes – 2. Post-IPO Share Option Scheme” in Appendix IV to the prospectus of the Company dated April 16, 2021

“RMB”	Renminbi, the lawful currency of the PRC
“Share(s)”	ordinary shares in the share capital of the Company of US\$0.00000025
“Share Option(s)”	the option(s) granted under the Post-IPO Share Option Scheme
“Share Option Grant”	an aggregate of 4,570,000 Share Options granted to the Grantees under the Post-IPO Share Option Scheme
“Share Option Grantee(s)”	any Eligible Participant(s) granted and/or proposed to be granted (as the case may be) the Share Options under the Post-IPO Share Option Scheme
“Shareholder(s)”	the holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“substantial shareholder(s)”	has the meaning ascribed thereto under the Listing Rules
“US\$”	United States dollars, the lawful currency of the United States
“%”	per cent

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, July 3, 2024

As at the date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.